| Bioactivity | Lanopepden (GSK 1322322) is a peptide deformylase inhibitor active against Staphylococcus aureus strains with MICs of 1 and 1 mg/L for ATCC 29213 and ATCC 25923 strain, respectively[1]. | ||||||||||||
| Name | Lanopepden | ||||||||||||
| CAS | 1152107-25-9 | ||||||||||||
| Formula | C22H34FN7O4 | ||||||||||||
| Molar Mass | 479.55 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Peyrusson F, et al. Cellular pharmacokinetics and intracellular activity of the novel peptide deformylase inhibitor GSK1322322 against Staphylococcus aureus laboratory and clinical strains with various resistance phenotypes: studies with human THP-1 monoc |
Lanopepden
CAS: 1152107-25-9 F: C22H34FN7O4 W: 479.55
Lanopepden (GSK 1322322) is a peptide deformylase inhibitor active against Staphylococcus aureus strains with MICs of 1
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.